Engine Biosciences, Singapore- and San Carlos, CA-based company deciphering complex biology to create medicines , raised $43m in Series A funding round.
The round was led by Polaris Partners qith participation from new investors Invus and one of the world’s premier institutional investors, based in Singapore, as well as existing investors 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio. Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors.
The company, which has now raised $53m to date, including $10m in a 2018 seed round, intends to use the funds to to expand its portfolio of precision oncology therapeutics, prepare for its first clinical programs, and scale its proprietary technology platform.
Led by Jeffrey Lu, Co-Founder and CEO, Engine Biosciences leverages complex biology to advance medicines. Its proprietary NetMAPPR platform integrates data science and machine learning, high-throughput biological experiments using patented CombiGEM combinatorial genetics system, computational and wet lab chemistry, and drug discovery to enable researchers and drug developers to uncover the gene interactions and biological networks underlying diseases. Additionally, the company generates important insights for precision medicine applications.
Engine has already been progressing its novel biology findings into drug discovery programs and proprietary small molecule inhibitors. It has performed several large-scale computational and experimental cycles with respect to genetic interactions and their relevance to multiple cancers, yielding new and subsequently validated discoveries.